22978-25-2 GW9662 AKSci J11414
 
 
Loading Please Wait...
  J11414    
GW9662
, 99% (HPLC), powder
 
2-Chloro-5-nitrobenzanilide




IDENTITY
CAS Number:22978-25-2
MDL Number:MFCD01215270
MF:C13H9ClN2O3
MW:276.68
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:99% (HPLC), powder
Physical Form (at 20°C):Solid
Melting Point:158-159°C
Long-Term Storage:Store long-term at 2-8°C
DOT/IATA TRANSPORT INFORMATION
Not hazardous material

REVIEW

 GW9662 is a selective PPAR antagonist for PPARγ with IC50 of 3.3 nM with at least 100 to 1000-fold functional selectivity in cells with PPARγ versus PPARα and PPARδ., respectively. IC50 Value: 3.3 nM(for PPARγ); 32 nM(for PPARα); 2 uM(for PPARδ) Target: PPARγ in vitro: GW9662 is a selective PPARγ antagonist (IC50 values are 3.3, 32 and 2000 nM for PPARγ, PPARα and PPARδ respectively). GW9662 blocks the inhibition of osteoclast formation induced by IL-4 in the low micromolar range (1-2 µM), therefore is more potent than BADGE. PPARγ antagonist GW9662 may inhibit the foam-cell formations in atherosclerosis. GW9662 induces functional estrogen receptor in mouse mammary organ culture. Anticancer, inhibits growth of human mammary tumor cell lines. The induction of ER-α by GW9662, including newer analogs, may permit use of anti-ER strategies to inhibit breast cancer in ER-patients. in vivo: Pretreatment with LPS (1 mg/kg i.p.) significantly attenuates all markers of renal injury and dysfunction caused by ischemia/reperfusion (I/R) injury in rats. Most notably, GW9662 (1 mg/kg i.p.) abolishes the protective effects of LPS.

REFERENCES
[1]Leesnitzer LM, Parks DJ, Bledsoe RK et al. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry. 2002 May 28;41(21):6640-50.
[2] Seargent JM, Yates EA, Gill JH. GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation. Br J Pharmacol. 2004 Dec;143(8):933-7. Epub 2004 Nov 8.
[3] Collino M, Patel NS, Lawrence KM, et al. The selective PPARgamma antagonist GW9662 reverses the protection of LPS in a model of renal ischemia-reperfusion. Kidney Int. 2005 Aug;68(2):529-36.
[4] Karen K Ryan, Bailing Li, Bernadette E Grayson, et al. A role for central nervous system PPAR-γ in the regulation of energy balance. Nature Medicine, 2011,17, 623-626.

GLOBALLY HARMONIZED SYSTEM (GHS)

Pictograms

Signal Word
Warning

Hazard Statements
H317; H319; H411

Precautionary Statements
P261; P264; P272; P273; P280; P302+P352; P305+P351+P338; P321; P333+P313; P337+P313; P363; P391; P501


Current as of April 19, 2024


Download SDS Request COA

All products are stocked and shipped from San Francisco Bay Area, California, USA.

⚠️
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.

These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.

Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.

New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.



CATEGORIES

 APIs and Bioactives > Anticancers


PubChem